[Studies on the tumorigenic action of streptozotocin and on the physiologic responses to glucose loading in tumor-bearing rats (author's transl)].

G. Yoshino,T. Kazumi,S. Baba
DOI: https://doi.org/10.1507/endocrine1927.54.9_1070
1978-09-20
Abstract:Pancreatic islet cell tumors were induced in 37 of 44 male Wistar rats (84%), surviving 9 to 14 months after treatment, not only by various doses of streptozotocin alone, but also by the combined administration of streptozotocin with nicotinamide or picolinamide. A single i.v. injection of 30, 40, 50 and 65 mg/kg body weight of streptozotocin alone produced adenomas of pancreatic islet cells in 8 out of 9 (89%), 6 out of 7 (86%), 2 out of 4 (50%) and 1 out of 2 rats (50%), respectively. The neoplasms were seen in all of the 8 rats given a single, 65 mg/kg body weight, i.v. injection of streptozotocin, preceded (15 min) by a single, 250 mg/kg body weight, i.p. injection of picolinamide. Among the 14 rats given a single, 500 mg/kg body weight, i.p. injection of nicotinamide, 15 min before a single i.v. injection of 65 mg/kg body weight of streptozotocin, 13 rats (93%) developed pancreatic islet cell adenomas. Renal tumors were seen in only 3 rats treated with streptozotocin and nicotinamide. Each of them had islet cell tumors of the pancreas. None ofthe rats used in this study developed hepatic tumors. Plasma insulin levels rose markedly following the glucose load in most of the rats with islet cell tumors, irrespective of the kind of treatment schedules, as compared to the response of the controls, whereas 4 out of 34 rats with islet cell tumors showed no insulin response to the glucose load and hyperglycemia. The present study demonstrates that streptozotocin, even ina dose of 30 mg/kg body weight, has an exceedingly marked tumorigenic action on therat endocrine pancreas, while it has slight effect on kidneys and little on livers. Observations on the physiologic responses
What problem does this paper attempt to address?